NYSE · CHEMICALS & ALLIED PRODUCTS · LARGE CAP
FMC Corporation FMC
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.5B
▼ 18.3% vs FY2024
EPS · FY25
$-17.88
Dividend / sh · FY25
$1.82
Payout · FY25
-13%
ROE · FY25
-68.3%
Net margin · FY25
-64.6%
Dividend coverage
-9.8×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.5B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 65 cents on every revenue dollar this year.
Per share
USD -17.88
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
-68.3%
Return on equity, FY2025
ROE
Operating margin-47.0%
Net margin-64.6%
Return on assets-21.0%
Each USD of equity lost 68 cents this year.
Returned to shareholders
USD 291.3M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 291.3M
Net buybacksUSD -200,000.00
Share of profit-13.0%
Consecutive raises—
USD 291.3M in dividends went back to shareholders in a year without profit.
Growth
−5.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−15.8%
−5.7%
+3.4%
+0.7%
Dividend / share
−5.7%
+0.2%
+10.7%
+14.1%
Returned to shareholders
−6.7%
+2.8%
+12.9%
+4.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 9.7B
total assets, end of FY2025
Total assetsUSD 9.7B
EquityUSD 2.1B
CashUSD 584.5M
Gross debtUSD 3.4B
Net debtUSD 2.8B
Current ratio1.32×
Net debt stands at 134% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
3.5
4.2
4.5
5.8
5.0
4.6
4.6
4.3
2.5
2.5
2.5
3.3
3.1
3.4
3.0
3.1
2.8
3.1
2.6
Operating income $B
−1.6
0.5
0.6
1.1
1.0
0.9
0.8
0.7
0.2
0.3
−0.1
0.4
0.5
0.6
0.6
0.4
0.3
0.5
0.2
EBITDA $B
−1.5
0.7
0.7
1.3
1.2
1.1
1.0
0.9
0.3
0.4
−0.1
0.5
0.6
0.8
0.7
0.5
0.5
0.6
0.4
Income tax $B
0.3
−0.2
−1.1
0.1
0.1
0.2
0.1
0.1
0.2
0.1
0.0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
Net income $B
−2.2
0.3
1.3
0.7
0.7
0.6
0.5
0.5
0.5
0.2
0.5
0.3
0.3
0.4
0.4
0.2
0.2
0.3
0.1
EPS, diluted $
−17.88
2.72
10.53
5.81
5.73
4.23
3.62
3.69
3.99
1.56
3.66
2.29
2.16
3.00
2.55
1.18
3.12
4.02
1.71
Dividend / sh $
1.82
2.32
2.32
2.17
1.96
1.80
1.64
0.90
0.66
0.66
0.66
0.60
0.54
0.41
0.30
0.25
0.50
0.48
0.41
Payout %
−13
85
22
36
33
41
44
18
17
42
18
25
25
11
11
21
16
11
22
ROE %
−68.3
7.7
33.9
22.7
24.3
20.1
16.9
17.3
23.1
10.9
28.8
20.2
19.6
30.6
30.9
15.6
23.1
33.7
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
70 of 70
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed